Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
| Autor: | WEINKOVE, Robert, PRISTUPA, Alexander, KASYCH, Muzhdaba, YAGCI, Munci, MARCO, Jose Antonio Garcia, Vural, Filiz, Kaynar, Leylagül, BURGER, J. A., ROBAK, T., TEDESCHI, A., Barr, P. M., Owen, C., GHIA, P., Bairey, O., HILLMEN, P., BARTLETT, N. L., LI, J., SIMPSON, D., GROSICKI, S., HAMBLIN, Michael, ATKINS, James, BARRIENTOS, Jaqueline, DUNCOMBE, Andrew, GASIC, Slavisa, HOU, Jing-Zhou, KINGSLEY, Edwin, SHADMAN, Mazyar, BADOUX, Xavier, GILL, Devinder, OPAT, Stephen, BRON, Dominique, VAN DEN NESTE, Eric, JING, Hongmei, ZHU, Jun, VANDENBERGHE, Elisabeth, TADMOR, Tamar, CORTELEZZI, Agostino, GANLY, Peter, PLUTA, Andrzej, DEVEREUX, S., MCCARTHY, H., COUTRE, S., QUACH, H., GAIDANO, G., MASLYAK, Z., STEVENS, D. A., JANSSENS, A., OFFNER, F., MAYER, J., O'DWYER, M., HELLMANN, A., Schuh, A., SIDDIQI, T., POLLIACK, A., TAM, C. S., SURI, D., CHENG, M., CLOW, F., STYLES, L., JAMES, D. F., KIPPS, T. J., TIRUMALI, Nagendra, QUACKENBUSH, Robert, FEGAN, Christopher, KEATING, Michael, JEN, Jie, JINDRA, Pavel, SIMKOVIC, Martin, BRAESTER, Andrei, RUCHLEMER, Rosa, FOA, Roberto, SEMENZATO, Gianpietro, HAWKINS, Timothy, ATANASIO, Carolina Moreno, Demirkan, Fatih, PYLYPENKO, Halyna, FOX, Christopher, THIRMAN, Michael, CAMPBELL, Philip, COUGHLIN, Paul, HARRUP, Rosemary, KUSS, Bryone, TURNER, Paul, WU, Ka Lung, LARRATT, Loree, FINEMAN, Riva, MARASCA, Roberto, ZINZANI, Pier Luigi, CORBETT, Gillian, ABRISQUETA, Pau, DELGADO, Julio, GONZALEZ-BARCA, Eva, DE OTEYZA, Jaime Perez, ARSLAND, Onder, KAPLAN, Polina, OLIYNYK, Hanna |
|---|---|
| Přispěvatelé: | Burger, Jan A, Tedeschi, Alessandra, Barr, Paul M, Robak, Tadeusz, Owen, Carolyn, Ghia, Paolo, Bairey, Osnat, Hillmen, Peter, Bartlett, Nancy L, Li, Jianyong, Simpson, David, Grosicki, Sebastian, Devereux, Stephen, Mccarthy, Helen, Coutre, Steven, Quach, Hang, Gaidano, Gianluca, Maslyak, Zvenyslava, Stevens, Don A, Janssens, Ann, Offner, Fritz, Mayer, Jiří, O'Dwyer, Michael, Hellmann, Andrzej, Schuh, Anna, Siddiqi, Tanya, Polliack, Aaron, Tam, Constantine S, Suri, Deepali, Cheng, Mei, Clow, Fong, Styles, Lori, James, Danelle F, Kipps, Thomas J, M.D., Ph.D., for the RESONATE-2 Investigators [.., Pier Luigi Zinzani, Antonietta Tedeschi, ], Burger, Ja, Tedeschi, A, Barr, Pm, Robak, T, Owen, C, Ghia, P, Bairey, O, Hillmen, P, Bartlett, Nl, Li, J, Simpson, D, Grosicki, S, Devereux, S, Mccarthy, H, Coutre, S, Quach, H, Gaidano, G, Maslyak, Z, Stevens, Da, Janssens, A, Offner, F, Mayer, J, O'Dwyer, M, Hellmann, A, Schuh, A, Siddiqi, T, Polliack, A, Tam, C, Suri, D, Cheng, M, Clow, F, Styles, L, James, Df, Kipps, Tj, for the RESONATE-2, Investigators |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
pci-32765 previously untreated patients Lymphoma Gastroenterology Medical and Health Sciences Medicaments antineoplàstics Antineoplastic Agent chemistry.chemical_compound 0302 clinical medicine chlorambucil Piperidines Obinutuzumab immune system diseases hemic and lymphatic diseases Antineoplastic agents Chronic Fatigue Cancer cll 0303 health sciences Leukemia Medicine (all) Hazard ratio tyrosine kinase Leucèmia General Medicine Hematology Duvelisib Lymphocytic 3. Good health Fludarabine Aged Antineoplastic Agents Chlorambucil Diarrhea Disease-Free Survival Female Humans Leukemia Lymphocytic Chronic B-Cell Neutropenia Pyrazoles Pyrimidines Survival Analysis 030220 oncology & carcinogenesis Ibrutinib 6.1 Pharmaceuticals RESONATE-2 Investigators Acalabrutinib medicine.drug Human medicine.medical_specialty Cèl·lules B Clinical Trials and Supportive Activities open-label 03 medical and health sciences Rare Diseases Clinical Research Internal medicine General & Internal Medicine medicine cancer Survival rate 030304 developmental biology B cells business.industry Adenine B-Cell fludarabine Evaluation of treatments and therapeutic interventions phase-3 trial Pirimidines Orphan Drug chemistry Pyrimidine Immunology Pyrazole cyclophosphamide business |
| Zdroj: | Dipòsit Digital de la UB Universidad de Barcelona The New England journal of medicine, vol 373, iss 25 |
| ISSN: | 0028-4793 |
| Popis: | Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, open-label, randomized phase 3 trial to compare two oral agents, ibrutinib and chlorambucil, in previously untreated older patients with CLL or small lymphocytic lymphoma. Background Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, open-label, randomized phase 3 trial to compare two oral agents, ibrutinib and chlorambucil, in previously untreated older patients with CLL or small lymphocytic lymphoma. METHODS We randomly assigned 269 previously untreated patients who were 65 years of age or older and had CLL or small lymphocytic lymphoma to receive ibrutinib or chlorambucil. The primary end point was progression-free survival as assessed by an independent review committee. RESULTS The median age of the patients was 73 years. During a median follow-up period of 18.4 months, ibrutinib resulted in significantly longer progression-free survival than did chlorambucil (median, not reached vs. 18.9 months), with a risk of progression or death that was 84% lower with ibrutinib than that with chlorambucil (hazard ratio, 0.16; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|